[
  {
    "ts": null,
    "headline": "Why Eli Lilly (LLY) Hit $1 Trillion as Obesity Drug Momentum Ignites Investor Optimism",
    "summary": "Eli Lilly recently became the first healthcare company to surpass a $1 trillion market capitalization, propelled by surging demand for its GLP-1-based diabetes and obesity drugs, Zepbound and Mounjaro, alongside significant pipeline developments and expanded Medicare and Medicaid coverage. This milestone reflects growing investor optimism about Eli Lilly's innovation pipeline, its manufacturing investments, and the potential for its upcoming oral obesity treatment to further transform the...",
    "url": "https://finnhub.io/api/news?id=b244e7017947bfa828ca6be5a23ec797818294293a036905e9e23bf8e83c56ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764194931,
      "headline": "Why Eli Lilly (LLY) Hit $1 Trillion as Obesity Drug Momentum Ignites Investor Optimism",
      "id": 137619050,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly recently became the first healthcare company to surpass a $1 trillion market capitalization, propelled by surging demand for its GLP-1-based diabetes and obesity drugs, Zepbound and Mounjaro, alongside significant pipeline developments and expanded Medicare and Medicaid coverage. This milestone reflects growing investor optimism about Eli Lilly's innovation pipeline, its manufacturing investments, and the potential for its upcoming oral obesity treatment to further transform the...",
      "url": "https://finnhub.io/api/news?id=b244e7017947bfa828ca6be5a23ec797818294293a036905e9e23bf8e83c56ca"
    }
  },
  {
    "ts": null,
    "headline": "Hard for Eli Lilly to move significantly higher from here in the short-term: Kessef Capital's Yaffee",
    "summary": "Len Yaffee, Kessef Capital, join 'Fast Money' to talk Amgen's obesity drug, Eli Lilly's current stock action, and much more.",
    "url": "https://finnhub.io/api/news?id=303b5ffda98d091833cda4518ed68b709c9b7ee68ad5481c0cbe374568362820",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764180201,
      "headline": "Hard for Eli Lilly to move significantly higher from here in the short-term: Kessef Capital's Yaffee",
      "id": 137622183,
      "image": "https://image.cnbcfm.com/api/v1/image/108232828-17641974871764197483-42711632075-1080pnbcnews.jpg?v=1764197486&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Len Yaffee, Kessef Capital, join 'Fast Money' to talk Amgen's obesity drug, Eli Lilly's current stock action, and much more.",
      "url": "https://finnhub.io/api/news?id=303b5ffda98d091833cda4518ed68b709c9b7ee68ad5481c0cbe374568362820"
    }
  },
  {
    "ts": null,
    "headline": "CMS Slashes Prices Of 15 Major Drugs - Here's Why Pharma Valuations Won't Suffer",
    "summary": "Discover how new U.S. Medicare drug price cuts impact major pharma stocks like Novo Nordisk and why sector resilience supports a strong outlook. Click for more.",
    "url": "https://finnhub.io/api/news?id=1f6a4babd9bee8ff46ea9bfd57aa2d2c9e4fb232cd4ea10363ae33b37483d4b4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764176336,
      "headline": "CMS Slashes Prices Of 15 Major Drugs - Here's Why Pharma Valuations Won't Suffer",
      "id": 137615519,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1407294139/image_1407294139.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover how new U.S. Medicare drug price cuts impact major pharma stocks like Novo Nordisk and why sector resilience supports a strong outlook. Click for more.",
      "url": "https://finnhub.io/api/news?id=1f6a4babd9bee8ff46ea9bfd57aa2d2c9e4fb232cd4ea10363ae33b37483d4b4"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's Moment: AI-Powered Pipeline Positions Shares to Surge in 2026",
    "summary": "Eli Lilly's stock is surging amid a flurry of AI deals. Our proprietary Zacks Rank system confirms the trend.",
    "url": "https://finnhub.io/api/news?id=17fee0e918b3b6d0041c32c128613a1763c9af7e00c40d9e2bda6ffa0c7f9870",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764174840,
      "headline": "Lilly's Moment: AI-Powered Pipeline Positions Shares to Surge in 2026",
      "id": 137614446,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's stock is surging amid a flurry of AI deals. Our proprietary Zacks Rank system confirms the trend.",
      "url": "https://finnhub.io/api/news?id=17fee0e918b3b6d0041c32c128613a1763c9af7e00c40d9e2bda6ffa0c7f9870"
    }
  },
  {
    "ts": null,
    "headline": "CURE: Analysts Strike A Cautious Tone Heading Into 2026",
    "summary": "Discover why the Direxion Healthcare Bull 3X ETF is outperforming in 2025. Learn about key risks, returns, and buy ratings.",
    "url": "https://finnhub.io/api/news?id=a5ef5754831c30f25c83c66be5e038c5194b41554790fb800b0ad9b7a81a6a4b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764174517,
      "headline": "CURE: Analysts Strike A Cautious Tone Heading Into 2026",
      "id": 137615429,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2009808479/image_2009808479.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover why the Direxion Healthcare Bull 3X ETF is outperforming in 2025. Learn about key risks, returns, and buy ratings.",
      "url": "https://finnhub.io/api/news?id=a5ef5754831c30f25c83c66be5e038c5194b41554790fb800b0ad9b7a81a6a4b"
    }
  },
  {
    "ts": null,
    "headline": "NVO Stock Up as Amycretin Shows Strong Weight Loss in Type 2 Diabetes",
    "summary": "Novo Nordisk jumps after phase II data show amycretin offers significant weight loss and HbA1c level reductions in type 2 diabetes patients.",
    "url": "https://finnhub.io/api/news?id=7422f7ebf24e12958fe290a02a04ecd3ed66d23588ed2de2710b3c019b0abfac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764171900,
      "headline": "NVO Stock Up as Amycretin Shows Strong Weight Loss in Type 2 Diabetes",
      "id": 137614447,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk jumps after phase II data show amycretin offers significant weight loss and HbA1c level reductions in type 2 diabetes patients.",
      "url": "https://finnhub.io/api/news?id=7422f7ebf24e12958fe290a02a04ecd3ed66d23588ed2de2710b3c019b0abfac"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: $1 Trillion Built On One Drug Segment",
    "summary": "Eli Lilly and Company is rated Sell due to extreme dependence on GLP-1 drugs & valuation that assumes near-perfect conditions. Read more on LLY stock here.",
    "url": "https://finnhub.io/api/news?id=b9d091b5669047849add1425356211798ae48e633f4597f557700da906989923",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764171805,
      "headline": "Eli Lilly: $1 Trillion Built On One Drug Segment",
      "id": 137615278,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2163791811/image_2163791811.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly and Company is rated Sell due to extreme dependence on GLP-1 drugs & valuation that assumes near-perfect conditions. Read more on LLY stock here.",
      "url": "https://finnhub.io/api/news?id=b9d091b5669047849add1425356211798ae48e633f4597f557700da906989923"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie and Pfizer: A Closer Look at Two Pharma Heavyweights",
    "summary": "ABBV's surging immunology sales and smoother LOE path stand out as both drugmakers face a pivotal 2026.",
    "url": "https://finnhub.io/api/news?id=6ac81ded30baa5da034478881631ffce1a918e07dea7f3e46eead3cfc0a99ab1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764171720,
      "headline": "AbbVie and Pfizer: A Closer Look at Two Pharma Heavyweights",
      "id": 137614448,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "ABBV's surging immunology sales and smoother LOE path stand out as both drugmakers face a pivotal 2026.",
      "url": "https://finnhub.io/api/news?id=6ac81ded30baa5da034478881631ffce1a918e07dea7f3e46eead3cfc0a99ab1"
    }
  },
  {
    "ts": null,
    "headline": "Stock Split Watch: Is Eli Lilly Next?",
    "summary": "The stock recently reached beyond $1,000.",
    "url": "https://finnhub.io/api/news?id=af652cea620ad4e4c8719b22c992501f9d7205a2459e045f2e53504a4bc1bb72",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764171000,
      "headline": "Stock Split Watch: Is Eli Lilly Next?",
      "id": 137614450,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The stock recently reached beyond $1,000.",
      "url": "https://finnhub.io/api/news?id=af652cea620ad4e4c8719b22c992501f9d7205a2459e045f2e53504a4bc1bb72"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Equity ETF (GDOC) Hits Fresh 52-Week High",
    "summary": "GDOC hits a 52-week high as aging demographics, tech advances and strength from top holding LLY fuel momentum.",
    "url": "https://finnhub.io/api/news?id=d1925fe95eb3d06f463ac9d42576bb21e5798992a7bf0131b06ad0b79d0b6032",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764167040,
      "headline": "Healthcare Equity ETF (GDOC) Hits Fresh 52-Week High",
      "id": 137614451,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "GDOC hits a 52-week high as aging demographics, tech advances and strength from top holding LLY fuel momentum.",
      "url": "https://finnhub.io/api/news?id=d1925fe95eb3d06f463ac9d42576bb21e5798992a7bf0131b06ad0b79d0b6032"
    }
  },
  {
    "ts": null,
    "headline": "BMO Launches New CDRs With Exposure to U.S. Stocks Including Microsoft, Eli Lilly, Exxon, Chevron and Robinhood",
    "summary": "Bank of Montreal (BMO) announced five new Canadian depositary receipts (CDRs) will begin trading on the Cboe Canada exchange today. The initial offering of these new CDRs has closed.",
    "url": "https://finnhub.io/api/news?id=591f8d13f7d4ec74df4d576a469d68995441deea3fedab35e7bef8837ff8a4da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764160200,
      "headline": "BMO Launches New CDRs With Exposure to U.S. Stocks Including Microsoft, Eli Lilly, Exxon, Chevron and Robinhood",
      "id": 137611101,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Bank of Montreal (BMO) announced five new Canadian depositary receipts (CDRs) will begin trading on the Cboe Canada exchange today. The initial offering of these new CDRs has closed.",
      "url": "https://finnhub.io/api/news?id=591f8d13f7d4ec74df4d576a469d68995441deea3fedab35e7bef8837ff8a4da"
    }
  },
  {
    "ts": null,
    "headline": "Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies",
    "summary": "Pharma companies are facing pricing pressure from several directions, including from the U.S. Medicare negotiations",
    "url": "https://finnhub.io/api/news?id=88b71e4c01ec422b59073a29aa50ec62b533a6d7d826368bff9384a4b21a2226",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764159509,
      "headline": "Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies",
      "id": 137613711,
      "image": "https://image.cnbcfm.com/api/v1/image/108226743-1763385742494-gettyimages-2212016375-NOVO_WEGOVY.jpeg?v=1763385821&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Pharma companies are facing pricing pressure from several directions, including from the U.S. Medicare negotiations",
      "url": "https://finnhub.io/api/news?id=88b71e4c01ec422b59073a29aa50ec62b533a6d7d826368bff9384a4b21a2226"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Discusses Eli Lilly (LLY) Touching the Trillion Dollar Market Value",
    "summary": "We recently published 11 Stocks Jim Cramer Shared His Insights On. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer discussed. Eli Lilly and Company (NYSE:LLY) is one of Cramer’s top stocks in the pharmaceutical space. He has remained optimistic about the firm throughout the year and praised its lead in the weight […]",
    "url": "https://finnhub.io/api/news?id=a1e53b0b80bf741f671df76ef880c2f4e150c221021a89cde0da2d72d6670a08",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764156593,
      "headline": "Jim Cramer Discusses Eli Lilly (LLY) Touching the Trillion Dollar Market Value",
      "id": 137611227,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published 11 Stocks Jim Cramer Shared His Insights On. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer discussed. Eli Lilly and Company (NYSE:LLY) is one of Cramer’s top stocks in the pharmaceutical space. He has remained optimistic about the firm throughout the year and praised its lead in the weight […]",
      "url": "https://finnhub.io/api/news?id=a1e53b0b80bf741f671df76ef880c2f4e150c221021a89cde0da2d72d6670a08"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Faces 71% Medicare Price Cuts on Ozempic and Wegovy",
    "summary": "U.S. government move slashes costs for key diabetes and weight-loss drugs beginning in 2027.",
    "url": "https://finnhub.io/api/news?id=ed506b972a72dcf0b5103dbeca95ddc5db03408d95df088cbc3f5b9b40472097",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764155609,
      "headline": "Novo Nordisk Faces 71% Medicare Price Cuts on Ozempic and Wegovy",
      "id": 137611228,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "U.S. government move slashes costs for key diabetes and weight-loss drugs beginning in 2027.",
      "url": "https://finnhub.io/api/news?id=ed506b972a72dcf0b5103dbeca95ddc5db03408d95df088cbc3f5b9b40472097"
    }
  },
  {
    "ts": null,
    "headline": "Hedge Funds Pile Into Health Stocks Leading Market in Rotation",
    "summary": "The S&P 500 Health Care Index is up 10% through Tuesday, outperforming the other 10 sectors in the benchmark for US stocks.  Eli Lilly & Co. has surged 29% to become the first health company with a $1 trillion valuation.  Regeneron Pharmaceuticals Inc., Merck & Co. and Biogen Inc. are all up at least 18% since the end of October.",
    "url": "https://finnhub.io/api/news?id=3768daf75b4e70ec346d2eb5b0e4f04e7f887660fac02bb04248c747f2d50a79",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764153000,
      "headline": "Hedge Funds Pile Into Health Stocks Leading Market in Rotation",
      "id": 137611229,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The S&P 500 Health Care Index is up 10% through Tuesday, outperforming the other 10 sectors in the benchmark for US stocks.  Eli Lilly & Co. has surged 29% to become the first health company with a $1 trillion valuation.  Regeneron Pharmaceuticals Inc., Merck & Co. and Biogen Inc. are all up at least 18% since the end of October.",
      "url": "https://finnhub.io/api/news?id=3768daf75b4e70ec346d2eb5b0e4f04e7f887660fac02bb04248c747f2d50a79"
    }
  },
  {
    "ts": null,
    "headline": "Did Pfizer Just Say \"Checkmate\" to Novo Nordisk?",
    "summary": "The weight loss drug market may approach almost $100 billion by the end of the decade.",
    "url": "https://finnhub.io/api/news?id=b30b4cd1f3a84357ae367cd118fe2c01deb185a5b1a837a9949b5ef9aa751525",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764148500,
      "headline": "Did Pfizer Just Say \"Checkmate\" to Novo Nordisk?",
      "id": 137611230,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The weight loss drug market may approach almost $100 billion by the end of the decade.",
      "url": "https://finnhub.io/api/news?id=b30b4cd1f3a84357ae367cd118fe2c01deb185a5b1a837a9949b5ef9aa751525"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Breakfast Podcast: HP Downsizes To Power Up",
    "summary": "HP slides after weak forecast, job cuts. Trump admin negotiates 71% discount on Ozempic, Wegovy for Medicare patients. Foxconn gets approval to invest additional $569M in Wisconsin.",
    "url": "https://finnhub.io/api/news?id=a942a62f72b23c608a451ab469f57d4acc8bca4a6924bb12b022b1ab556113b8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764139839,
      "headline": "Wall Street Breakfast Podcast: HP Downsizes To Power Up",
      "id": 137610661,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/497444610/image_497444610.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "HP slides after weak forecast, job cuts. Trump admin negotiates 71% discount on Ozempic, Wegovy for Medicare patients. Foxconn gets approval to invest additional $569M in Wisconsin.",
      "url": "https://finnhub.io/api/news?id=a942a62f72b23c608a451ab469f57d4acc8bca4a6924bb12b022b1ab556113b8"
    }
  },
  {
    "ts": null,
    "headline": "JPMorgan Raises Eli Lilly (LLY) Price Target to $1,150, Maintains Overweight Rating",
    "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 15 Best Stocks to Buy for Medium Term. On‍ November 18, JPMorgan analyst Chris Scho‍tt r‌aised the firm‍’s‍ price ta‌rg​et on Eli Lilly and Company (NYSE:LLY) to $1,150 from $1,050 wh‍ile maintaining an Overw‍eig​ht ratin⁠g after meetings with management. JPMorgan said the di‌scu‌ss⁠ions‌ re‌inforced its positive […]",
    "url": "https://finnhub.io/api/news?id=7e8635288d3741e58ff8490d63c115cc6b9ea7db73ea89eb47e61c43f49e079f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764137311,
      "headline": "JPMorgan Raises Eli Lilly (LLY) Price Target to $1,150, Maintains Overweight Rating",
      "id": 137611231,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 15 Best Stocks to Buy for Medium Term. On‍ November 18, JPMorgan analyst Chris Scho‍tt r‌aised the firm‍’s‍ price ta‌rg​et on Eli Lilly and Company (NYSE:LLY) to $1,150 from $1,050 wh‍ile maintaining an Overw‍eig​ht ratin⁠g after meetings with management. JPMorgan said the di‌scu‌ss⁠ions‌ re‌inforced its positive […]",
      "url": "https://finnhub.io/api/news?id=7e8635288d3741e58ff8490d63c115cc6b9ea7db73ea89eb47e61c43f49e079f"
    }
  },
  {
    "ts": null,
    "headline": "Trump administration slashes Ozempic and Wegovy price for Medicare",
    "summary": "The US government has negotiated a 71 per cent discount for Novo Nordisk’s weight-loss drugs Ozempic and Wegovy for patients enrolled in Medicare...",
    "url": "https://finnhub.io/api/news?id=2bb7925fbb7033900802b33e9d5c2abeb0bb77587d53892f8fad367af95ac96d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764121977,
      "headline": "Trump administration slashes Ozempic and Wegovy price for Medicare",
      "id": 137611232,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The US government has negotiated a 71 per cent discount for Novo Nordisk’s weight-loss drugs Ozempic and Wegovy for patients enrolled in Medicare...",
      "url": "https://finnhub.io/api/news?id=2bb7925fbb7033900802b33e9d5c2abeb0bb77587d53892f8fad367af95ac96d"
    }
  }
]